23 March 2011
Left ventricular assist device as ‘bridge to weight loss’ prior to transplantation in obese patients with advanced heart failure
Pavittarpaul DhesiABCDEF, Sinan A. SimsirAE, Daniel DaneshvarBC, Asim RafiqueBC, Anita PhanADEF, Ernst R. SchwarzADEFAnn Transplant 2011; 16(1): 5-13 :: ID: 881632
Abstract
Background: Obesity is a risk factor for heart failure (HF) and associated with poor outcomes after cardiac transplantation.
We assessed change in total body weight, morbidity and mortality in obese heart failure patients after implantation of a left ventricular assist device (LVAD) compared to medical management.
Material/Methods: Nineteen patients (9 females, age 51.3±10 years) with a body mass index (BMI) ≥30.0 kg/m2 and advanced HF (NYHA class III–IV, stage D) were evaluated. Thirteen (group 1) received insertion of a LVAD as bridge to transplantation. The remaining patients (group 2) were medically managed. All were advised on lifestyle modification.
Results: At baseline, group 1 (49.1±10.7 years) had a total body weight (BW) of 246.6±34.9 pounds (mean ±SD) and a BMI of 36.1±4 kg/m2. Group 2 (56±6.7 yrs) had a BW of 238.8±73.6 pounds and a BMI of 39.1±9.3 kg/m2 (n.s. compared to group 1). All patients were alive at 12 months. At 6 months, BW in group 1 was reduced to 216.3±20.8 pounds, and BMI to 31.8±3.3 kg/m2 (p<0.05). At 6 months, BW in group 2 was 238.2±84.6 pounds, and BMI was 39.1±11.6 kg/m2 (n.s. vs. baseline, p<0.05 compared to group 1). The decrease in BW in group 1 was 12.3±12% (30.3±28.5 pounds). There was no change in BW in group 2 (0.3±8.7%, 0.6±21 pounds, p<0.05 vs. group 1). At 12 months, 7 patients in group 1 (54%) underwent cardiac transplantation.
Conclusions: LVAD insertion resulted in weight loss in obese patients not considered for heart transplantation compared to medically managed patients.
Keywords: left ventricular assist device, obesity, Weight Loss, cardiac transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






